Chronic idiopathic urticaria
Information
- Disease name
- Chronic idiopathic urticaria
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02814630 | Completed | N/A | Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria | September 2016 | November 2, 2018 |
| NCT00264303 | Completed | Phase 4 | CUTE (Chronic Urticaria Treatment Evaluation) | December 2005 | January 2007 |
| NCT00536380 | Completed | Phase 4 | Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) | September 2007 | April 2009 |
| NCT00757562 | Completed | Phase 3 | Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994) | November 1, 2002 | October 1, 2003 |
| NCT00783354 | Completed | Phase 4 | A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) | April 1, 2003 | April 1, 2004 |
| NCT00866788 | Completed | Phase 2 | A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) | March 2009 | January 2010 |
| NCT03183024 | Completed | Phase 4 | Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody | September 12, 2017 | November 6, 2018 |
| NCT01264939 | Completed | Phase 3 | A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists | February 2011 | November 2012 |
| NCT01287117 | Completed | Phase 3 | A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment | February 2011 | October 2012 |
| NCT01292473 | Completed | Phase 3 | A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) | March 2011 | June 2012 |
| NCT01599637 | Completed | Phase 2 | Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment | April 2012 | September 2013 |
| NCT03858634 | Completed | Phase 2 | A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases | May 29, 2019 | June 8, 2020 |
| NCT01803763 | Completed | Phase 2/Phase 3 | Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients | September 2012 | March 2014 |
| NCT02031679 | Completed | Phase 2 | Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines | January 2014 | January 2016 |
| NCT03406325 | Completed | Mast Cell Activation Test in Allergic Disease | February 1, 2018 | December 1, 2019 | |
| NCT04175704 | Not yet recruiting | Phase 1 | Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria | December 30, 2023 | January 30, 2026 |
| NCT05936567 | Recruiting | Phase 2 | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria | July 31, 2023 | September 5, 2025 |
| NCT05774639 | Recruiting | Phase 3 | Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria | August 15, 2023 | April 3, 2025 |
| NCT01635127 | Unknown status | Phase 2 | Efficacy Study of Canakinumab to Treat Urticaria | June 2012 | May 2017 |
| NCT00346606 | Unknown status | Phase 4 | The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria | January 2006 | |
| NCT02166151 | Unknown status | Phase 3 | Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria | July 2014 | June 2016 |
| NCT01030120 | Withdrawn | Phase 2/Phase 3 | Etanercept for the Treatment of Chronic Urticaria | December 2010 | October 2012 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0410133